S. Møller, K. Grunnet, S. Hansen, H. Schult, M. Holmberg, and M. Sorensen, “A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy”, AO, vol. 51, no. 6, pp. 797–804, Jul. 2012.